John F Seymour

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. ncbi request reprint Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma
    John F Seymour
    Department of Hematology, The Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    Cancer 94:585-93. 2002
  2. ncbi request reprint The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization
    Colm Keane
    Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia
    Hematol Oncol 24:159-63. 2006
  3. pmc Overview of early response assessment in lymphoma with FDG-PET
    Michael P MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Cancer Imaging 7:10-8. 2007
  4. pmc Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
    John F Seymour
    Peter MacCallum Cancer Centre, Melbourne, Vic, Australia Victorian Comprehensive Cancer Centre, Parkville, Melbourne, Vic, Australia Faculty of Medicine, University of Melbourne, Parkville, Melbourne, Vic, Australia Electronic address
    Lancet Oncol . 2017
  5. pmc Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan
    Haruyuki Ishii
    Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, 1 754 Asahimachi dori, Chuo Ku, Niigata 9518520, Japan
    BMC Pulm Med 14:37. 2014
  6. pmc R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes
    John F Seymour
    Peter MacCallum Cancer Centre, East Melbourne, Australia University of Melbourne, Parkville, Australia
    Haematologica 99:1343-9. 2014
  7. pmc Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield
    T Seshadri
    Monash Medical Centre, Clayton, Victoria 3168, Australia
    Br J Cancer 94:1007-10. 2006
  8. ncbi request reprint Extra-pulmonary aspects of acquired pulmonary alveolar proteinosis as predicted by granulocyte-macrophage colony-stimulating factor-deficient mice
    John F Seymour
    Peter MacCallum Cancer Centre, Victoria, Australia
    Respirology 11:S16-22. 2006
  9. pmc Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes
    John F Seymour
    Peter MacCallum Cancer Centre and University of Melbourne, Victoria 3002, Australia
    Crit Rev Oncol Hematol 76:218-27. 2010
  10. ncbi request reprint Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure
    Ashley P Ng
    Haematology Service, PeterMacCallum Cancer Centre, Melbourne, Australia
    Leuk Lymphoma 48:596-600. 2007

Detail Information

Publications110 found, 100 shown here

  1. ncbi request reprint Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma
    John F Seymour
    Department of Hematology, The Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    Cancer 94:585-93. 2002
    ....
  2. ncbi request reprint The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization
    Colm Keane
    Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia
    Hematol Oncol 24:159-63. 2006
    ..There were no significant differences in PBSC yields following cycles 2A, 2B and 3A. Hyper-CVAD has substantial stem cell toxicity which can be readily circumvented by using the early chemotherapy cycles for mobilization...
  3. pmc Overview of early response assessment in lymphoma with FDG-PET
    Michael P MacManus
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, VIC 3002, Australia
    Cancer Imaging 7:10-8. 2007
    ....
  4. pmc Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
    John F Seymour
    Peter MacCallum Cancer Centre, Melbourne, Vic, Australia Victorian Comprehensive Cancer Centre, Parkville, Melbourne, Vic, Australia Faculty of Medicine, University of Melbourne, Parkville, Melbourne, Vic, Australia Electronic address
    Lancet Oncol . 2017
    ..Combination therapy with rituximab enhanced activity in preclinical models. The aim of this study was to assess the safety, pharmacokinetics, and activity of venetoclax in combination with rituximab...
  5. pmc Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan
    Haruyuki Ishii
    Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, 1 754 Asahimachi dori, Chuo Ku, Niigata 9518520, Japan
    BMC Pulm Med 14:37. 2014
    ..However, the impact of sPAP on the prognosis of underlying MDS remains unknown. The purpose of this study was to evaluate whether development of sPAP worsens the prognosis of MDS...
  6. pmc R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes
    John F Seymour
    Peter MacCallum Cancer Centre, East Melbourne, Australia University of Melbourne, Parkville, Australia
    Haematologica 99:1343-9. 2014
    ..The MAIN study is registered at clinicaltrials.gov identifier:00486759. ..
  7. pmc Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield
    T Seshadri
    Monash Medical Centre, Clayton, Victoria 3168, Australia
    Br J Cancer 94:1007-10. 2006
    ..Furthermore, the quality of tissue harvested does not appear to be adversely affected by patient's age or prior ABVD chemotherapy...
  8. ncbi request reprint Extra-pulmonary aspects of acquired pulmonary alveolar proteinosis as predicted by granulocyte-macrophage colony-stimulating factor-deficient mice
    John F Seymour
    Peter MacCallum Cancer Centre, Victoria, Australia
    Respirology 11:S16-22. 2006
    ....
  9. pmc Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes
    John F Seymour
    Peter MacCallum Cancer Centre and University of Melbourne, Victoria 3002, Australia
    Crit Rev Oncol Hematol 76:218-27. 2010
    ..Given this efficacy and tolerability, AZA should be considered the treatment of choice in patients aged ≥ 75 years with good performance status and higher-risk MDS...
  10. ncbi request reprint Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure
    Ashley P Ng
    Haematology Service, PeterMacCallum Cancer Centre, Melbourne, Australia
    Leuk Lymphoma 48:596-600. 2007
    ..Low-grade FDG-avidity on interim restaging at sites of bone involvement by DLBCL at diagnosis, appears to be less predictive of disease progression than residual nodal or extra-nodal soft tissue abnormality by PET...
  11. ncbi request reprint Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma
    Constantine S Tam
    Leukemia Lymphoma Service, Hematology Service, Peter MacCallum Cancer Center, The Alfred Hospital, University of Melbourne, Victoria, Australia
    Cancer 106:2412-20. 2006
    ..The combination of fludarabine, cyclophosphamide, and rituximab (FC-R) shows significant in vitro synergism and may improve patient outcome with little overlapping toxicity...
  12. doi request reprint Mantle cell lymphoma with central nervous system involvement: frequency and clinical features
    Saar Gill
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Br J Haematol 147:83-8. 2009
    ..While not routinely justified for all patients, CNS prophylaxis may particularly benefit patients with blastic histology at diagnosis, or those with systemic relapse after first-line treatment...
  13. doi request reprint Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma
    Nicole Wong Doo
    Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Leuk Lymphoma 54:1465-72. 2013
    ..We propose that its use should be explored as part of a tandem approach in patients undergoing initial SCT who are at high risk of early relapse...
  14. doi request reprint Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients
    Saar Gill
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Ann Hematol 87:727-34. 2008
    ..These results indicate a considerable rate of prolonged haematological toxicity after hyper-CVAD and a modest rate of MDS at this limited follow-up. These findings likely reflect cumulative damage to haematopoietic stem cells...
  15. ncbi request reprint Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia
    Constantine S Tam
    Department of Haematology, Peter MacCallum Cancer Centre, A Beckett Street, East Melbourne, Victoria 8006, Australia
    Clin Lymphoma Myeloma 6:136-9. 2005
    ..No cases of secondary myelodysplasia or leukemia were encountered...
  16. doi request reprint A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
    Simon J Harrison
    Haematology Department, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Blood 118:6274-83. 2011
    ..2 (95% CI: 5.5-19.6) months, and the median OS was > 36 months. This regimen shows activity with manageable toxicity and warrants further evaluation. This trial was registered at www.clinicaltrials.gov as NCT00431990...
  17. doi request reprint [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma
    Saar Gill
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Clin Lymphoma Myeloma 8:159-65. 2008
    ..Positron emission tomography (PET) is an important imaging modality in the staging and response assessment of patients with lymphoma, but data on its specific use in mantle cell lymphoma (MCL) are lacking...
  18. doi request reprint Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy
    Thomas E Lew
    a Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia
    Leuk Lymphoma 57:1044-53. 2016
    ..Dose attenuated FCR appears to have preserved efficacy and may be a viable therapeutic option for elderly patients with CLL...
  19. ncbi request reprint The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders
    Mark N Polizzotto
    Department of Hematology, The Alfred Hospital, Melbourne, Victoria, Australia
    Cancer 107:773-80. 2006
    ..Despite the prevalence of such disorders in older patients, the effect of increasing age on the deliverability of these regimes has not been assessed...
  20. ncbi request reprint A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
    H Miles Prince
    University of Melbourne and Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Clin Cancer Res 11:5504-14. 2005
    ..Future studies should use newer COX-2 inhibitors with thalidomide, or their respective derivatives...
  21. doi request reprint Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy
    Chan Y Cheah
    Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, East Melbourne, 8006, Victoria, Australia
    Ann Hematol 93:1193-200. 2014
    ..Thus, surveillance imaging of patients with TrIL achieving CMR is of limited clinical benefit. PET-CT should be reserved for evaluation of clinically suspected relapse. ..
  22. doi request reprint Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy
    Michael Dickinson
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    Br J Haematol 150:39-45. 2010
    ..Although those with positive scans can still be salvaged with current treatments, PET may useful for selecting patients eligible for novel consolidation strategies after salvage therapies...
  23. doi request reprint Predicting durable remissions following thalidomide therapy for relapsed myeloma
    Hang Quach
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    Leuk Lymphoma 50:223-9. 2009
    ..001). The OS for these groups were >69.8, 35.4 and 11.7 months, respectively (p < 0.001). These findings support the therapeutic goal of achieving 'maximum depth of response' in patients with relapsed myeloma...
  24. doi request reprint Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia
    Stefan Peinert
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Leuk Lymphoma 51:2188-97. 2010
    ..F-combination therapy is highly active in WM, both untreated and alkylator-refractory. However, a possible contribution to the cumulative risk of treatment-related MDS/AML requires ongoing monitoring...
  25. doi request reprint Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    Andrew W Roberts
    From the Department of Clinical Haematology and the Bone Marrow Transplantation Unit, Royal Melbourne Hospital A W R, M A A, the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research A W R, M A A, and the Victorian Comprehensive Cancer Centre A W R, J F S, Parkville, Vic, and the University of Melbourne A W R, J F S and Peter MacCallum Cancer Centre J F S, Melbourne, VIC all in Australia Dana Farber Cancer Institute, Boston M S D, J R B the Swedish Medical Center, Seattle J M P Washington University, St Louis B S K University of Arizona, Tucson S D P Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York J F G University of California, San Diego, San Diego T J K AbbVie, North Chicago, IL L G, S W, M D, M Z, M B D, E C, S H E, R A H and University of Texas M D Anderson Cancer Center, Houston W G W
    N Engl J Med 374:311-22. 2016
    ..Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells...
  26. doi request reprint A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation
    Amit Khot
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Clin Lymphoma Myeloma Leuk 13:42-7. 2013
    ..We prospectively explored a strategy that used prophylactic delayed filgrastim only in patients with risk factors...
  27. ncbi request reprint A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies
    Constantine S Tam
    Leukemia Lymphoma Service, Department of Hematology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer 101:2042-9. 2004
    ..The authors analyzed their experience with patients treated with the fludarabine-mitoxantrone (FM) or fludarabine-cyclophosphamide (FC) regimens to develop a predictive model for infections...
  28. ncbi request reprint Management of the primary cutaneous lymphomas
    H Miles Prince
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Australas J Dermatol 44:227-40; quiz 241-2. 2003
    ..Newer therapies include the synthetic retinoid bexarotene, the immunotoxin conjugate denileukin diftitox, interleukin-12 and monoclonal antibodies such as alemtuzumab and rituximab...
  29. doi request reprint Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
    John F Seymour
    Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Vic, Australia
    Br J Haematol 165:49-56. 2014
    ..92% and 88% vs. 75%). Azacitidine OS results are consistent with those from AZA-001, regardless of cellularity, and demonstrate its safety and efficacy in higher-risk myelodysplasia with hypocellular BM. ..
  30. ncbi request reprint Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation
    Ashley P Ng
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia
    Haematologica 90:1672-9. 2005
    ....
  31. doi request reprint Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis
    Gabrielle M Haeusler
    Department of Infectious Diseases and Infection Control, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia
    Eur J Haematol 91:157-63. 2013
    ..The objective of this study was to review the incidence of PJP during and post-FCR in the era of highly sensitive molecular diagnostics and (18) F-fluorodeoxyglucose (FDG) positron emission tomography (PET)-computerised tomography (CT)...
  32. ncbi request reprint Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders
    Simon D J Gibbs
    Haematology Service, Peter MacCallum Cancer Centre, Victoria, Australia
    Br J Haematol 130:87-91. 2005
    ..Alemtuzumab can be associated with prolonged severe multilineage cytopenias, marrow hypoplasia and myelodysplasia in T-cell LPD...
  33. doi request reprint Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma
    Andrew Wirth
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Int J Radiat Oncol Biol Phys 71:213-9. 2008
    ..We evaluated the impact of fluorodeoxyglucose (FDG) PET on staging, treatment, and outcome for patients with ESFL on conventional staging...
  34. doi request reprint The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review
    Chan Y Cheah
    Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Leuk Lymphoma 56:49-56. 2015
    ..Thus a negative PET-CT is an excellent predictor of subsequent outcome. However, residual metabolically active masses after treatment should be biopsied to confirm viable lymphoma prior to salvage therapy...
  35. ncbi request reprint Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*
    Karin A Thursky
    Department of Infectious Diseases, Peter MacCallum Cancer Centre, Victoria, Australia
    Br J Haematol 132:3-12. 2006
    ..This review discusses the infection risks associated with these lymphoproliferative disorders and their treatment, and provide detailed recommendations for screening and prophylaxis...
  36. ncbi request reprint Treatment-related myelodysplasia following fludarabine combination chemotherapy
    Constantine S Tam
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Haematologica 91:1546-50. 2006
    ..5% for previously untreated patients, and 9.3% for pretreated patients (p=0.28). The rate of MDS/sAML following fludarabine combination therapy is higher than that previously reported for fludarabine monotherapy...
  37. doi request reprint Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit
    Tan N Doan
    Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia
    J Antimicrob Chemother 71:497-505. 2016
    ..Secondary objectives were to determine risk factors for IFD and resource utilization associated with IFD...
  38. doi request reprint A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma
    Paul L R Mitchell
    Austin Hospital, Melbourne, Australia
    Leuk Lymphoma 49:924-31. 2008
    ..The high rate of infectious complications suggests that the DaunoXome dose used may be too high for this patient group. These results support further investigation of this regimen in patients with aggressive NHL...
  39. ncbi request reprint What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?
    Saar Gill
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Australia
    Leuk Lymphoma 49:1653-6. 2008
  40. doi request reprint Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
    Matthew S Davids
    Matthew S Davids, Dana Farber Cancer Institute, Boston, MA Andrew W Roberts, John F Seymour, and Mary Ann Anderson, University of Melbourne Andrew W Roberts and Mary Ann Anderson, Royal Melbourne Hospital and Eliza Hall Institute of Medical Research and John F Seymour, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia John M Pagel, Swedish Cancer Institute, Seattle, WA Brad S Kahl, Washington University Medical School, St Louis, MO William G Wierda, University of Texas MD Anderson Cancer Center, Houston, TX Soham Puvvada, University of Arizona, Tucson, AZ Thomas J Kipps, University of California San Diego, San Diego, CA Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Jeremy A Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A Humerickhouse, and Gary B Gordon, AbbVie, Chicago, IL Ahmed Hamed Salem, Japan
    J Clin Oncol . 2017
    ..Additional investigations including combination therapy to augment response rates and durability are ongoing...
  41. ncbi request reprint Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies
    Constantine S Tam
    Hematology Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Cancer 100:2181-9. 2004
    ..In the current study, the authors analyzed their experience with an attenuated dose regimen to determine whether equivalent efficacy could be achieved with reduced toxicity...
  42. ncbi request reprint Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring
    Linda Mileshkin
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Clin Oncol 24:4507-14. 2006
    ..We assessed the time course of occurrence, possible predictive factors, and the utility of serial nerve electrophysiological studies (NES) for detecting onset of neuropathy...
  43. ncbi request reprint A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy
    H Miles Prince
    Hematology Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Biol Blood Marrow Transplant 11:512-20. 2005
    ..022) and in the duration of intravenous opiates ( P=.0006). We conclude that PV701 mouthwash is readily administered with minimal side effects at a dose of 1215 mg/d, and further investigation of this agent is warranted...
  44. doi request reprint The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation
    Shaun Fleming
    The Royal Melbourne Hospital, Victoria, Australia Electronic address
    Clin Lymphoma Myeloma Leuk 14:291-6. 2014
    ..Mucositis rates are influenced by previous chemotherapy (CT) exposure. We examined the effect of induction therapy before ASCT on ASCT mucositis rates...
  45. pmc Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib
    Chan Y Cheah
    Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia University of Melbourne, Parkville, Vic, Australia
    Blood 123:3574-7. 2014
    ..Imatinib is well-tolerated and achieves excellent long-term responses in patients with PDGFRB rearrangements. ..
  46. ncbi request reprint Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma
    John F Seymour
    Department of Haematology, The Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    J Clin Oncol 21:2115-22. 2003
    ..We investigated the potential for combined-modality therapy to increase the disease-free survival for such patients...
  47. ncbi request reprint Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: role of rituximab, high-dose therapy, and allogeneic stem cell transplantation
    Shriram V Nath
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Leuk Lymphoma 46:1075-9. 2005
    ..The specific roles of the components of the successful salvage therapy are discussed...
  48. doi request reprint Primary testicular lymphoma
    Chan Y Cheah
    Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Melbourne, Vic, Australia
    Blood 123:486-93. 2014
    ..Finally, we discuss new treatment approaches and recent discoveries that may translate into improved outcomes for patients with PTL. ..
  49. pmc Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease
    Andrew W Roberts
    MBBS, Department of Clinical Haematology and BMT, The Royal Melbourne Hospital, 2 Centre, Grattan St, Parkville 3050, Victoria, Australia
    J Clin Oncol 30:488-96. 2012
    ..A phase I trial in patients with CLL was conducted to evaluate the safety, pharmacokinetics, and biologic activity of oral navitoclax...
  50. doi request reprint A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment
    Senthil Lingaratnam
    Pharmacy Department, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
    Aust Health Rev 35:491-500. 2011
    ....
  51. ncbi request reprint Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia
    Fiona Chionh
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    Leuk Lymphoma 46:603-5. 2005
    ..Thus, in patients with hematological malignancies who develop significant gastrointestinal symptoms, we recommend that endoscopic investigations and biopsies are performed to exclude IA as a potential cause...
  52. ncbi request reprint Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk
    Leon J Worth
    Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Eur J Haematol 79:226-33. 2007
    ..Vancomycin-resistant enterococci (VRE) are significant nosocomial pathogens in patients with hematologic malignancy. Identification of risk factors for infection is necessary for targeted prevention and surveillance...
  53. doi request reprint Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices
    Leon J Worth
    Centre for Clinical Research Excellence in Infectious Disease, Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, Victoria, 3052, Australia
    Support Care Cancer 17:811-8. 2009
    ..The objectives of this study were to determine the natural history and rate of CVC-related complications and risk factors for CR-BSI and to compare device-specific complications in a hematology population...
  54. ncbi request reprint Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
    Andrew Wirth
    Division of Radiation Oncology, Peter McCallum Cancer Institute, East Melbourne, Victoria, Australia
    Am J Med 112:262-8. 2002
    ..To compare fluorine-18 fluorodeoxyglucose positron emission tomography (PET) and gallium scanning with each other and with conventional staging, for patients with Hodgkin's disease or non-Hodgkin's lymphoma...
  55. ncbi request reprint Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers
    Gail F Ryan
    Peter MacCallum Cancer Centre, Melbourne, Australia
    Clin Lymphoma Myeloma 6:337-41. 2006
    ..Targeted strategies such as CNS prophylaxis and contralateral breast irradiation might therefore improve prognosis and should be prospectively studied...
  56. doi request reprint Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis
    Senthil M Lingaratnam
    Pharmacy Department, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Leuk Lymphoma 56:157-62. 2015
    ..2%], 3/118 [2.5%] and 1/61 [1.6%], respectively). A risk-based tool incorporating concomitant steroid therapy can be applied to target high-risk populations who would benefit from PJP prophylaxis during gemcitabine therapy...
  57. doi request reprint Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy
    Siow Chin Heng
    Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
    J Antimicrob Chemother 68:1669-78. 2013
    ..This study evaluated the clinical and economic outcomes of these agents when used in AML patients undergoing consolidation chemotherapy...
  58. ncbi request reprint Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome
    Simon D J Gibbs
    Haematology Service, Peter MacCallum Cancer Centre, Melbourne, Australia
    Eur J Haematol 73:447-9. 2004
    ..We present the case of a 65-yr-old man who was successfully treated with alemtuzumab monotherapy for both disorders, but at a cost of severe infectious morbidity and prolonged pancytopenia...
  59. ncbi request reprint Leukaemic subtype of marginal zone lymphoma: a presentation of three cases and literature review
    Constantine S Tam
    Haematology Service, Peter MacCallum Cancer Centre, St Andrew s Place, East Melbourne, Victoria, Australia
    Leuk Lymphoma 45:705-10. 2004
    ..We review the current literature on this newly described entity, highlighting the importance of its recognition...
  60. ncbi request reprint The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement
    Janine Campbell
    Division of Laboratory Services, Royal Children s Hospital, Parkville, Victoria, Australia
    Eur J Haematol 76:473-80. 2006
    ..Factors that that have been reported to influence prognosis include the pattern and extent of marrow infiltration and histological discordance between the primary site and the bone marrow...
  61. doi request reprint Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients
    Stephen D Guy
    Department of Infectious Diseases, Western Health, Private Bag, Footscray, Victoria, Australia 3011
    Eur J Nucl Med Mol Imaging 39:1348-55. 2012
    ..The aim of this study was to prospectively evaluate the clinical utility of FDG PET/CT in patients with cancer and severe neutropenia and five or more days of persistent fever despite antibiotic therapy...
  62. doi request reprint Surveillance for catheter-associated bloodstream infection in hematology units: quantifying the characteristics of a practical case definition
    Leon J Worth
    Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Infect Control Hosp Epidemiol 29:358-60. 2008
    ..0% sensitivity and 94.3% specificity. This case definition provides a practical method for effectively excluding CVC-associated bloodstream infection...
  63. pmc Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia
    Adrian R Tramontana
    Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    Emerg Infect Dis 16:1068-75. 2010
    ..Oseltamivir resistance in 4 (13.3%) of 30 patients who were administered oseltamivir highlights the need for ongoing surveillance of such resistance and further research on optimal antiviral therapy in the immunocompromised...
  64. ncbi request reprint Initial staging of lymphoma with positron emission tomography and computed tomography
    Rodney J Hicks
    Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 Cathedral Place, East Melbourne, Victoria 3002, Australia
    Semin Nucl Med 35:165-75. 2005
    ..In our institution, FDG PET/CT has become the preferred initial staging tool for patients with lymphoma...
  65. pmc The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
    Mary Ann Anderson
    Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Vic, Australia Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Vic, Australia Department of Clinical Hematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, Vic, Australia
    Blood 127:3215-24. 2016
    ..These data provide direct evidence that venetoclax kills CLL cells in a TP53-independent fashion by inhibition of BCL2 in patients and support further assessment of BH3 profiling as a predictive biomarker for this drug. ..
  66. doi request reprint The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution
    Kirsten E Herbert
    Peter MacCallum Cancer Centre, Department of Hematology and Medical Oncology, Victoria, Australia
    Expert Opin Biol Ther 10:113-25. 2010
    ..The emergence of other novel agents for HSPC mobilization such as plerixafor (AMD3100, Mozobil) will further demarcate the role of Ancestim as a second- or third-line mobilization agent for the mobilization-refractory patient...
  67. ncbi request reprint Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience
    Wirawan Jeong
    Centre for Medicine Use and Safety, Monash University, Vic, Australia
    J Antimicrob Chemother 71:3540-3547. 2016
    ....
  68. doi request reprint Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies
    Siow Chin Heng
    Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
    Diagn Microbiol Infect Dis 79:322-7. 2014
    ..Use of BAL GM and PCR improves the diagnosis of IPA...
  69. ncbi request reprint New treatment approaches to indolent non-Hodgkin's lymphoma
    John F Seymour
    Department of Hematology, Peter MacCallum Cancer Center, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Semin Oncol 31:27-32. 2004
    ....
  70. ncbi request reprint Pulmonary alveolar proteinosis. What is the role of GM-CSF in disease pathogenesis and treatment?
    John F Seymour
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Treat Respir Med 3:229-34. 2004
  71. ncbi request reprint Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma
    Robert H Blum
    Division of Hematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Clin Lymphoma 4:43-9. 2003
    ..This high accuracy of FDG-PET in assessing discordant lesions suggests a greater diagnostic utility compared with CT...
  72. ncbi request reprint Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells
    H Miles Prince
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia
    Br J Haematol 126:536-45. 2004
    ..There were also fewer platelet transfusions required (43% vs. 100%; P = 0.009). We conclude that EXE cells enhance both neutrophil and platelet recovery and reduce febrile neutropenia, platelet transfusion and hospital re-admission...
  73. ncbi request reprint Alveolar soft-part sarcoma: a cardiac metastasis as a rare site of relapse
    Belinda Campbell
    Peter MacCallum Cancer Centre, Melbourne, Australia
    Am J Clin Oncol 29:422-3. 2006
  74. ncbi request reprint Pulmonary alveolar proteinosis
    Jeffrey J Presneill
    Intensive Care Unit, Royal Melbourne Hospital, Grattan Street, Parkville 3050, Victoria, Australia
    Clin Chest Med 25:593-613, viii. 2004
    ..The last decade has brought new advances in laboratory and clinical research that are lifting a veil not only on PAP but also on general aspects of pulmonary surfactant biology and innate immune defense...
  75. pmc Negative selection of chronic lymphocytic leukaemia cells using a bifunctional rosette-based antibody cocktail
    Salim Essakali
    Department of Pathology, Peter MacCallum Cancer Centre, St Andrews Place, Melbourne, Victoria 3002, Australia
    BMC Biotechnol 8:6. 2008
    ..High purity of tumour samples is a necessity for accurate genetic and expression analysis and is usually achieved by positive selection in chronic lymphocytic leukaemia (CLL)...
  76. pmc Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia
    Angela Y C Tan
    Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia
    J Hematol Oncol 1:10. 2008
    ..High resolution melting (HRM) is a novel screening method that enables rapid identification of mutation positive DNA samples...
  77. ncbi request reprint Mice lacking three myeloid colony-stimulating factors (G-CSF, GM-CSF, and M-CSF) still produce macrophages and granulocytes and mount an inflammatory response in a sterile model of peritonitis
    Margaret L Hibbs
    Signal Transduction Laboratory, Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Royal Melbourne Hospital, Victoria, and Department of Medicine, University of Melbourne, Parkville, Australia
    J Immunol 178:6435-43. 2007
    ..These data establish that in the absence of G-CSF, GM-CSF, and M-CSF, additional growth factor(s) can stimulate myelopoiesis and acute inflammatory responses...
  78. ncbi request reprint Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib
    David S Ritchie
    Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, No 1 A Beckett Street, Melbourne, Victoria 8006, Australia
    Blood 111:2896-8. 2008
    ..Furthermore, we report that sustained molecular remission has been achieved despite withdrawal of tyrosine kinase inhibitor (TKI) therapy...
  79. doi request reprint Indolent lymphomas other than follicular and marginal zone lymphomas
    Stefan Peinert
    Department of Haematology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, East Melbourne, Victoria 8006, Australia
    Hematol Oncol Clin North Am 22:903-40, viii. 2008
    ..Differential diagnoses and prognostic factors are discussed for each as well as new treatment options and stem cell transplantation...
  80. doi request reprint Primary breast lymphoma
    Chan Y Cheah
    Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Melbourne, Victoria, Australia University of Melbourne, Parkville, Melbourne, Victoria, Australia Electronic address
    Cancer Treat Rev 40:900-8. 2014
    ..We conclude with a suggested treatment approach and potential areas of future research. ..
  81. doi request reprint Rituximab for the treatment of follicular lymphoma
    Chan Y Cheah
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Future Oncol 9:1283-98. 2013
    ..The toxicities are modest and manageable, including infusion reactions, late-onset neutropenia, impaired humoral immunity, reactivation of hepatitis and possibly pulmonary toxicity. ..
  82. doi request reprint Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency
    Chan Y Cheah
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia
    Acta Haematol 130:254-9. 2013
    ..Asymptomatic decrease in oxygen saturation by oximetry and cyanosis are signs of methemoglobinemia; patients recover with conservative measures including supplemental oxygen and packed red cell transfusion. ..
  83. ncbi request reprint Surveillance of second cancer after previous childhood cancer treatment
    Sally K Ng
    St Vincent s Hospital, Fitzroy, Victoria, Australia
    Aust Fam Physician 36:643-5. 2007
    ..With the introduction of new therapeutic strategies, the survival of children and adolescents with cancer has increased dramatically. However, cancer survivors often experience late effects from their cancer treatment...
  84. ncbi request reprint The Late Effects Clinic in action: for survivors of childhood malignancy
    Belinda A Campbell
    Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
    Acta Oncol 46:1152-8. 2007
    ..We present three case reports illustrating the value of a formal late effects follow-up programme, and demonstrating the integration of the Late Effects Clinic into medical practice...
  85. ncbi request reprint Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
    Linda Mileshkin
    Department of Haematology and Medical Oncology, and Statistical Centre, Peter MacCallum Cancer Institute, St Andrew s Place, East Melbourne, Victoria 3002, Australia
    Blood 102:69-77. 2003
    ..Interferon may improve response in selected patients, but is often not tolerated. The inferior outcome demonstrated in those with the identified prognostic factors is important in planning management for such patients...
  86. ncbi request reprint Clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer and World Health Organization classifications
    Lee Mei Yap
    The University of Melbourne, Department of Medicine Dermatology, St Vincent s Hospital Melbourne, Victoria, Australia
    Australas J Dermatol 44:110-5. 2003
    ..Further large prospective studies comparing the WHO and EORTC classifications are required to more clearly delineate the outcomes of the increasing number of patients who are classified as DLBCL by the WHO system...
  87. doi request reprint High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma
    Raghava Kashyap
    Centre for Cancer Imaging, Peter MacCallum Cancer Centre, St Andrews Place, Melbourne, Australia 3002
    Eur J Nucl Med Mol Imaging 40:1330-6. 2013
    ..PET/CT has a major role in lymphoma imaging, but glycolytic activity in inflammatory processes can reduce specificity. In this study we evaluated restaging PET/CT findings in patients with non-Hodgkin lymphoma (NHL) and fat necrosis...
  88. ncbi request reprint Role of 18FDG-positron emission tomography scanning in the management of histiocytosis
    Robert Blum
    Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Locked Bag 1, A Beckett Street, East Melbourne, Victoria, 8006 Australia
    Leuk Lymphoma 43:2155-7. 2002
    ..Functional imaging with 18FDG PET provides a potential method for non-invasively detecting active disease. We report two cases where this modality was positive and facilitated therapeutic monitoring...
  89. ncbi request reprint Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
    Susan Branford
    Division of Molecular Pathology, Institute of Medical and Veterinary Science, South Australia 5000, Australia
    Blood 102:276-83. 2003
    ..0001. In conclusion, the detection of kinase domain mutations using a direct sequencing technique was almost always associated with imatinib resistance, and patients with mutations in the P-loop had a particularly poor prognosis...
  90. ncbi request reprint High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis
    Kanji Uchida
    Department of Respiratory Diseases, Research Institute, International Medical Center of Japan, 1 21 1 Toyama, Shinjuku City, Tokyo 162 8655, Japan
    Blood 103:1089-98. 2004
    ..Our data strengthen the evidence associating anti-GM-CSF autoantibodies with the pathogenesis of this disease...
  91. ncbi request reprint Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression
    Susan J Morgan
    Clin Cancer Res 10:3572-5. 2004
  92. ncbi request reprint Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
    Susan Branford
    Division of Molecular Pathology, Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 104:2926-32. 2004
    ..0001. Thus, a more than 2-fold rise identified 34 (97%) of 35 patients with a mutation. We conclude that a rise in BCR-ABL of more than 2-fold can be used as a primary indicator to test patients for BCR-ABL kinase domain mutations...
  93. ncbi request reprint Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'
    Andres J M Ferreri
    Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy
    Br J Haematol 127:173-83. 2004
    ..ECOG-PS >1, 'cutaneous variant', stage I and chemotherapy use were independently associated with improved survival...
  94. ncbi request reprint Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies
    Constantine Tam
    Haematologica 90:700-2. 2005
    ..This retrospective analysis of 160 patients treated with FC+/-rituximab found no evidence of increased infection among patients receiving FC+rituximab, providing some evidence of safety for the continued exploration of this regimen...
  95. ncbi request reprint Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP
    D Wayne Thomas
    Department of Haematology, Derriford Hospital, Plymouth, UK
    Leuk Lymphoma 46:549-52. 2005
    ..07 vs. CHOP), and a median duration of response of 11 months (4-25+ months). This study demonstrates that FC is a highly active regimen in patients relapsing following CHOP chemotherapy...
  96. ncbi request reprint A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma
    Dirk Honemann
    Leuk Lymphoma 46:945-7. 2005
  97. ncbi request reprint Defining the cost of cure: infertility among female survivors of lymphoma
    Catharyn J Stern
    Reproductive Services, Melbourne IVF, The Royal Women s Hospital, Australia
    Leuk Lymphoma 47:574-5. 2006
  98. ncbi request reprint Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma
    Michael F Leahy
    Department of Haematology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia
    J Clin Oncol 24:4418-25. 2006
    ..To evaluate efficacy and safety of iodine-131 (131I) -rituximab chimeric anti-CD20 antibody radioimmunotherapy in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)...
  99. ncbi request reprint Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular
    Roswitha Forstpointner
    Department of Internal Medicine III, University of Munich, Grosshadern Marchioninistr 15, 81377 Munchen, Germany
    Blood 108:4003-8. 2006
    ..035) and MCL (P = .049) separately. Hence, R-maintenance is effective after salvage with R-chemotherapy and significantly prolongs response duration in patients with recurring or refractory FL or MCL...
  100. ncbi request reprint Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders
    Marianna David
    Department of Haematology, University of Pecs, Pecs, Hungary
    Blood 109:61-4. 2007
    ..Our data show that durable hematologic and cytogenetic responses are achieved with imatinib in patients with PDGFRB fusion-positive, BCR-ABL-negative CMPDs...
  101. ncbi request reprint Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy
    Steven W Lane
    Department of Haematology, School of Medicine, University of Queensland, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Australia 4102
    Leuk Lymphoma 47:1813-7. 2006
    ..Once per cycle dosing of pegfilgrastim appears safe and as effective as daily G-CSF for supporting the hyper-CVAD chemotherapy regimen...